{"id":3465,"date":"2024-11-18T10:00:55","date_gmt":"2024-11-18T09:00:55","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=3465"},"modified":"2024-11-11T11:14:44","modified_gmt":"2024-11-11T10:14:44","slug":"durable-response-with-pemigatinib-in-cholangiocarcinoma","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/","title":{"rendered":"Durable response with pemigatinib in cholangiocarcinoma"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;Pemigatinib showed a prolonged overall survival and manageable adverse events in an open label study in patients with previously treated advanced cholangiocarcinoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]The selective, potent, oral inhibitor of fibroblast growth factor receptor1-3 (FGFR1-3) pemigatinib induces a durable response in patients with previously treated advanced or metastatic cholangiocarcinoma, as shown by the open label study FIGHT-202, whose results <a href=\"https:\/\/www.esmoopen.com\/article\/S2059-7029(24)01257-2\/fulltext\" target=\"_blank\" rel=\"noopener\">have been published recently on ESMO Open<\/a>.<\/p>\n<p>Authors enrolled 147 with previously treated advanced or metastatic cholangiocarcinoma with or without FGF\/FGFR alterations; participants received once-daily oral pemigatinib 13.5 mg in 21-day cycles (2 weeks on, 1 week off) until disease progression or unacceptable toxicity. The results from the extended follow-up period (median 45.4 months) show that objective response rate in the group with FGFR2 fusions or rearrangements was 37%, with complete and partial responses observed in 3 and 37 patients, respectively. Median duration of response was 9.1 months and median progression-free survival and overall survival were 7 and 17.5 months, respectively. 10.2% of patients experienced treatment-related adverse events leading to treatment discontinuation. As authors conclude, \u00abThis final analysis of FIGHT-202 demonstrated continued durable response, prolonged overall survival and manageable adverse events in patients with previously treated advanced or metastatic cholangiocarcinoma with <em>FGFR2<\/em> fusions or rearrangements, further supporting regulatory approvals of pemigatinib based on this single-arm, phase II study. These results highlight the need for early molecular testing in cholangiocarcinoma. The phase III FIGHT-302 study will further elucidate the role of FGFR inhibitors in biomarker-selected cholangiocarcinoma. Routine comprehensive genomic profiling is needed to discover novel actionable <em>FGFR2<\/em> alterations and identify patients who might benefit from FGFR inhibition\u00bb.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;2306&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;Pemigatinib showed a prolonged overall survival and manageable adverse events in an open label study in patients with previously treated advanced cholangiocarcinoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]The<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":2307,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-3465","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Durable response with pemigatinib in cholangiocarcinoma - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"Pemigatinib showed a prolonged overall survival and manageable adverse events in an open label study in patients with previously treated advanced cholangiocarcinoma\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Durable response with pemigatinib in cholangiocarcinoma - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"Pemigatinib showed a prolonged overall survival and manageable adverse events in an open label study in patients with previously treated advanced cholangiocarcinoma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-18T09:00:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/12\/Depositphotos_102728682_XL.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Durable response with pemigatinib in cholangiocarcinoma\",\"datePublished\":\"2024-11-18T09:00:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/\"},\"wordCount\":310,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Depositphotos_102728682_XL.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/\",\"name\":\"Durable response with pemigatinib in cholangiocarcinoma - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Depositphotos_102728682_XL.jpg\",\"datePublished\":\"2024-11-18T09:00:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"Pemigatinib showed a prolonged overall survival and manageable adverse events in an open label study in patients with previously treated advanced cholangiocarcinoma\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Depositphotos_102728682_XL.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Depositphotos_102728682_XL.jpg\",\"width\":2500,\"height\":1500,\"caption\":\"Cancer Treatment - Medical Concept with Blurred Text, Stethoscope, Pills and Syringe on Red Background. Selective Focus. 3D Render.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/durable-response-with-pemigatinib-in-cholangiocarcinoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Durable response with pemigatinib in cholangiocarcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Durable response with pemigatinib in cholangiocarcinoma - Fondazione Gianni Bonadonna","description":"Pemigatinib showed a prolonged overall survival and manageable adverse events in an open label study in patients with previously treated advanced cholangiocarcinoma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/","og_locale":"en_US","og_type":"article","og_title":"Durable response with pemigatinib in cholangiocarcinoma - Fondazione Gianni Bonadonna","og_description":"Pemigatinib showed a prolonged overall survival and manageable adverse events in an open label study in patients with previously treated advanced cholangiocarcinoma","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2024-11-18T09:00:55+00:00","og_image":[{"width":2500,"height":1500,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/12\/Depositphotos_102728682_XL.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Durable response with pemigatinib in cholangiocarcinoma","datePublished":"2024-11-18T09:00:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/"},"wordCount":310,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/12\/Depositphotos_102728682_XL.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/","name":"Durable response with pemigatinib in cholangiocarcinoma - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/12\/Depositphotos_102728682_XL.jpg","datePublished":"2024-11-18T09:00:55+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"Pemigatinib showed a prolonged overall survival and manageable adverse events in an open label study in patients with previously treated advanced cholangiocarcinoma","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/12\/Depositphotos_102728682_XL.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/12\/Depositphotos_102728682_XL.jpg","width":2500,"height":1500,"caption":"Cancer Treatment - Medical Concept with Blurred Text, Stethoscope, Pills and Syringe on Red Background. Selective Focus. 3D Render."},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/durable-response-with-pemigatinib-in-cholangiocarcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Durable response with pemigatinib in cholangiocarcinoma"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=3465"}],"version-history":[{"count":0,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3465\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/2307"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=3465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=3465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=3465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}